United States: Trials & Appeals & Compensation

The United States District Court for the Eastern District of California, applying California law, has held that a misappropriation of funds exclusion barred coverage under an E&O policy for a claim against a company that provided an allegedly negligent pre-employment background check.

Expulsion provisions in partnership and LLC agreements implicate a familiar tension between private ordering and abuse of power.

A Magistrate's Report in the Delaware Court of Chancery recently held that a judgment creditor of an individual could not reach the assets the individual had contributed...

In this episode of "The Trial Lawyer's Handbook" podcast, litigation attorney Dan Small discusses the value of observing and learning from experienced colleagues, both professionally and socially.

In Patterson v. Meta Platforms, Inc., the New York Appellate Division, Fourth Department, held in a split decision that Section 230 of the Communications Decency Act ("Section 230")––a federal statute that prohibits treating providers of "interactive computer services" as publishers of third-party content ––barred tort causes of action that sought to hold several social media companies liable for their algorithmic content recommendations.

The aflibercept multi-district litigation consists of multiple actions consolidated in the Northern District of West Virginia, with Regeneron Pharmaceuticals, Inc. ("Regeneron") filing suit under the Biologics...

The U.S. Supreme Court's decision in Harrington v. Purdue Pharma LP has, in many respects, changed the landscape for nonconsensual third-party releases in chapter 11 cases.

Since the U.S. Supreme Court in Bristol-Myers Squibb Co. v. Superior Court of California, 582 U.S. 255 (2017) (Bristol-Myers) determined that the trial court lacked specific jurisdiction over...

On September 25, 2025, the U.S. District Court for the Northern District of Texas issued a significant decision vacating a rule issued by the Centers for Medicare & Medicaid Services that would have had far-reaching ramifications for Medicare Advantage organizations subject to risk adjustment data validation audits by CMS.